Last $54.05 USD
Change Today +0.03 / 0.06%
Volume 12.1M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 6:40 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$54.22
Previous Close
$54.02
Day High
$54.27
Day Low
$53.92
52 Week High
09/8/14 - $61.33
52 Week Low
11/1/13 - $44.62
Market Cap
155.9B
Average Volume 10 Days
13.5M
EPS TTM
$3.58
Shares Outstanding
2.9B
EX-Date
09/11/14
P/E TM
15.1x
Dividend
$1.76
Dividend Yield
3.26%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

Merck Announces Final Results of Tender Offers for Eight Series of Notes

Merck & Co. Inc. announced the final results of the previously announced offers to purchase any and all of eight series outstanding notes. On Oct. 6, 2014, Merck commenced the Offers in accordance with the terms and conditions set in the Offer to Purchase, dated Oct. 6, 2014. The Offers expired at 5:00 p.m., New York City time, on Oct. 14, 2014. Payment for the Notes accepted pursuant to the Offers will be made on the expected settlement date Oct. 15, 2014. The applicable purchase price for each series of Notes will be paid together with accrued and unpaid interest from, and including, the last interest payment date for such series of Notes to, but excluding, the Settlement Date.

A Federal Judge Turns Back an Effort by Merck & Co. to Dismiss $100 Million Lawsuit Filed by Female Sales Representatives

A federal judge turned back an effort by lawyers for Merck & Co. to dismiss a $100 million lawsuit filed by female sales representatives who claim the drugmaker fosters a 'boys club' that rewards male 'breadwinners' with promotions and demotes women after they return from pregnancy leave. U.S. District Court Judge Joel Pisano did not rule on the merits of the class action lawsuit but said the women have raised issues that are 'plausible'. Merck said it will continue to defend itself against the allegations. The lawsuit was filed in May 2013 by five female Merck employees on behalf of others who may find themselves in a similar situation. They claim female sales representatives, particularly those who were pregnant, were paid less than male employees. It claims Merck's personnel decisions were rooted in stereotypes that view men as 'breadwinners' responsible for the sole support of their families while women should 'stay at home' with children. The lawsuit claims women who complained were repeatedly shot down by upper level managers. Among the plaintiffs is Kelli Smith, a senior sales representative for the company from June 2004 through December 2013. Smith claims she was paid less than male employees for the same job and demoted after she returned from pregnancy leave.

Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA(R) (Pembrolizumab) in Patients with Advanced Gastric Cancer At ESMO 2014

Merck announced the first presentation of data on the investigational use of KEYTRUDA(R) (pembrolizumab) -- the company's anti-PD-1 therapy -- in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31% with KEYTRUDA as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12/39: 95% CI, 17-47). Similar overall response rates were observed in Asian patients (a population with a high incidence of gastric cancer) and non-Asian patients. At the time of analysis, response durations ranged from 8+ to 20+ weeks with 11 of 12 responders continuing on therapy. These data, from a cohort of the ongoing Phase 1b KEYNOTE-012 study, were presented as part of a late-breaking oral session, by Dr. Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan, at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain (ABSTRACT #LBA15). Data investigating the use of KEYTRUDA monotherapy in five tumor types will be presented at ESMO 2014. KEYTRUDA is indicated in the United States at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Data from a cohort of the ongoing Phase 1b KEYNOTE-012 study evaluated KEYTRUDA monotherapy at 10 mg/kg every two weeks in patients with advanced gastric cancer whose tumors were determined to be positive for PD-L1 expression (n=39). As measured by Merck's proprietary immunohistochemistry (IHC) clinical trial assay, tumors were classified as PD-L1 positive based on greater than or equal to 1% of tumor cells demonstrating expression of the PD-L1 marker, or any positive staining with the same reagent in tumor stroma. Enrollment was designed to include an equal number of Asian and non-Asian patients. The majority of patients had received two or more prior lines of therapy. Using a prototype assay for PD-L1 assessment, there was evidence of a preliminary relationship between PD-L1 expression and ORR (P = 0.071). In the study, tumor shrinkage was demonstrated in 41% of evaluable patients who had measurable disease with one post baseline scan, per RECIST v1.1 criteria. Adverse events were consistent with previously reported safety data for KEYTRUDA. The most common investigator-assessed, treatment-related adverse events (occurring in greater than 5%) included hypothyroidism (12.8%) and fatigue (12.8%). Grade 3-5 investigator-assessed, treatment-related adverse events occurred in a total of three patients, with one patient each in peripheral sensory neuropathy (Grade 3), hypoxia (Grade 5) and pneumonitis (Grade 4). No infusion-related reactions were observed and no patients discontinued KEYTRUDA due to a treatment-related adverse reaction. One treatment-related death due to hypoxia, as assessed by the investigator, was reported.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $54.05 USD +0.03

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $137.60 USD +0.20
Bayer AG €102.76 EUR -1.75
Gilead Sciences Inc $102.21 USD +1.46
Pfizer Inc $27.93 USD +0.10
Roche Holding AG SFr.268.60 CHF +0.90
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 28.5x
Price/Sales 3.6x
Price/Book 3.2x
Price/Cash Flow 27.8x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.